Advertisement

Topics

EU and US Submissions for Single Tablet Combining Dolutegravir and Rilpivirine Priority Review Voucher Submitted in US with Anticipated Target Action Date of 6 Months

01:06 EDT 1 Jun 2017 | Drugs.com

London, UK 01 June 2017 – GSK and ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced regulatory submissions to the European Medicines Agency (EMA) and US...

Original Article: EU and US Submissions for Single Tablet Combining Dolutegravir and Rilpivirine Priority Review Voucher Submitted in US with Anticipated Target Action Date of 6 Months

NEXT ARTICLE

More From BioPortfolio on "EU and US Submissions for Single Tablet Combining Dolutegravir and Rilpivirine Priority Review Voucher Submitted in US with Anticipated Target Action Date of 6 Months"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

AIDS and HIV
AIDS; Acquired Immune Deficiency Syndrome. HIV; Human Immunodeficiency Virus HIV infection causes AIDS. HIV infection also causes the production of anti-HIV antibodies, which forms the test for HIV in patients. People who have the HIV antibodies are ...